Workit Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual addiction treatment platform for alcohol and opioid use disorder, Ann Arbor MI, raised $118M+. Combines medication-assisted treatment with digital coaching.
About
Workit Health is an Ann Arbor, Michigan-based virtual addiction treatment company founded in 2015 that provides evidence-based treatment for opioid use disorder (OUD) and alcohol use disorder (AUD) through a telehealth platform. The company has raised over $118 million and operates in multiple US states, delivering medication-assisted treatment (MAT) including buprenorphine prescribing alongside behavioral health coaching and peer support — all accessible from a member's smartphone.\n\nWorkit Health's model addresses the primary barriers to addiction treatment: stigma, geographic access, and cost. By delivering care via telehealth, the platform reaches patients in rural areas and communities where addiction specialists are scarce. The company accepts Medicaid in multiple states, making treatment accessible to lower-income patients who are disproportionately impacted by the opioid crisis. Clinicians on the platform conduct initial assessments by video, prescribe medications electronically, and monitor patient progress through regular virtual check-ins and app-based engagement tools.\n\nThe platform includes a structured digital program with skills-based modules covering triggers, coping strategies, and recovery maintenance, delivered alongside clinical care. Workit Health competes with Bicycle Health, Ophelia, and Boulder Care in the virtual MAT market. The company has expanded to serve employers and health plans as well as direct consumers, positioning it as both a consumer-facing addiction recovery resource and a value-based care solution for payers managing high-cost substance use disorder populations.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.